Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison With OnabotulinumtoxinA (Botox®) When Treating Adults With Upper Limb Spasticity

NCT04936542 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT04936542
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04936542 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport®) in Comparison With OnabotulinumtoxinA (Botox®) When Treating Adults With Upper Limb Spasticity
Lead sponsor
Ipsen
Phase
Phase 4
Overall status
Completed
Start date
June 23, 2021
Completion date
August 26, 2025
Enrollment
464 (actual)
Sites
76

Conditions

As the registry lists them; a condition with its own page is linked.

upper limb spasticity